Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 11 (4)

Potential Protective Mechanisms of Ketone Bodies in Migraine Prevention

Affiliations
Review

Potential Protective Mechanisms of Ketone Bodies in Migraine Prevention

Elena C Gross et al. Nutrients.

Abstract

An increasing amount of evidence suggests that migraines are a response to a cerebral energy deficiency or oxidative stress levels that exceed antioxidant capacity. The ketogenic diet (KD), a diet mimicking fasting that leads to the elevation of ketone bodies (KBs), is a therapeutic intervention targeting cerebral metabolism that has recently shown great promise in the prevention of migraines. KBs are an alternative fuel source for the brain, and are thus likely able to circumvent some of the abnormalities in glucose metabolism and transport found in migraines. Recent research has shown that KBs-D-β-hydroxybutyrate in particular-are more than metabolites. As signalling molecules, they have the potential to positively influence other pathways commonly believed to be part of migraine pathophysiology, namely: mitochondrial functioning, oxidative stress, cerebral excitability, inflammation and the gut microbiome. This review will describe the mechanisms by which the presence of KBs, D-BHB in particular, could influence those migraine pathophysiological mechanisms. To this end, common abnormalities in migraines are summarised with a particular focus on clinical data, including phenotypic, biochemical, genetic and therapeutic studies. Experimental animal data will be discussed to elaborate on the potential therapeutic mechanisms of elevated KBs in migraine pathophysiology, with a particular focus on the actions of D-BHB. In complex diseases such as migraines, a therapy that can target multiple possible pathogenic pathways seems advantageous. Further research is needed to establish whether the absence/restriction of dietary carbohydrates, the presence of KBs, or both, are of primary importance for the migraine protective effects of the KD.

Keywords: beta-hydroxybutyrate; exogenous ketone bodies; ketogenic diet; ketone bodies; ketosis; migraine; migraine prevention.

Conflict of interest statement

E.C.G. is the founder of KetoSwiss AG and E.C.G. and D.F. are the inventors of the patent WO 2018/115158 Al) held by the UKBB and University of Basel. D.P.D. is inventor on International Patent # PCT/US2014/031237, University of South Florida, “Compositions and Methods for Producing Elevated and Sustained Ketosis”. D.P.D. is co-owners of the company Ketone Technologies LLC. These interests have been reviewed and managed by the University in accordance with its Institutional and Individual Conflict of Interest policies. R.J.K. and J.S. have no conflicts of interest for this publication.

Figures

Figure 1
Figure 1
Potentially migraine relevant mechanisms of ketosis. (a) Amongst key migraine pathophysiological mechanisms are hypometabolism, decreased glucose transport (including glucose transporter 1 (GLUT1) deficiency), reduced mitochondrial functioning, increased cerebral excitability, increased cortical spreading depressions (CSD) incidence, increased oxidative stress (reactive oxygen species (ROS)), increased inflammation, microbiome abnormalities and reduced digestive health. (b) D-β-hydroxybutyrate (D-BHB; with or without the context of a ketogenic diet) has been shown to positively influence each of these mechanisms: increasing cerebral metabolism, increasing glucose transport (including glucose transporter 1 (GLUT1) deficiency), increasing mitochondrial functioning, reducing cerebral excitability, decreasing cortical spreading depressions (CSD) incidence, reducing oxidative stress (reactive oxygen species (ROS)), decreasing inflammation, improving the microbiome and increasing digestive health. ATP = adenosine triphosphate; CSD = cortical spreading depressions; D-BHB = D-β-hydroxybutyrate; GLUT1 = glucose transporter 1; ROS = reactive oxygen species.

Similar articles

See all similar articles

Cited by 3 articles

References

    1. Stovner L.J., Hoff J.M., Svalheim S., Gilhus N.E. Neurological disorders in the Global Burden of Disease 2010 study. Acta Neurol. Scand. 2014;129:1–6. doi: 10.1111/ane.12229. - DOI - PubMed
    1. Stovner L.J., Hagen K. Prevalence, burden, and cost of headache disorders. Curr. Opin. Neurol. 2006;19:281–285. doi: 10.1097/01.wco.0000227039.16071.92. - DOI - PubMed
    1. Olesen J., Gustavsson A., Svensson M., Wittchen H.-U., Jönsson B. The economic cost of brain disorders in Europe. Eur. J. Neurol. 2012;19:155–162. doi: 10.1111/j.1468-1331.2011.03590.x. - DOI - PubMed
    1. Buse D.C., Lipton R.B. Global perspectives on the burden of episodic and chronic migraine. Cephalalgia Int. J. Headache. 2013;33:885–890. doi: 10.1177/0333102413477736. - DOI - PubMed
    1. Sprenger T., Goadsby P.J. Migraine pathogenesis and state of pharmacological treatment options. BMC Med. 2009;7:71 doi: 10.1186/1741-7015-7-71. - DOI - PMC - PubMed
Feedback